The $1.7 trillion revenue prescription drug industry has a relatively robust immunity to tariffs. Last Wednesday, when U.S. President Donald Trump unveiled a raft of duties on countries and industries he held back on hitting pharmaceuticals.

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

The proposed tariffs on pharmaceutical products will not only impact India, but American citizens as well. Here is why.